JP2017513476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513476A5 JP2017513476A5 JP2016562499A JP2016562499A JP2017513476A5 JP 2017513476 A5 JP2017513476 A5 JP 2017513476A5 JP 2016562499 A JP2016562499 A JP 2016562499A JP 2016562499 A JP2016562499 A JP 2016562499A JP 2017513476 A5 JP2017513476 A5 JP 2017513476A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody variable
- antigen binding
- region
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14164523.4A EP2930188A1 (en) | 2014-04-13 | 2014-04-13 | Trifunctional antigen-binding molecule |
| EP14164523.4 | 2014-04-13 | ||
| PCT/EP2015/057919 WO2015158636A1 (en) | 2014-04-13 | 2015-04-12 | Trifunctional antigen-binding molecule |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513476A JP2017513476A (ja) | 2017-06-01 |
| JP2017513476A5 true JP2017513476A5 (enExample) | 2018-05-31 |
| JP6635940B2 JP6635940B2 (ja) | 2020-01-29 |
Family
ID=50478320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562499A Expired - Fee Related JP6635940B2 (ja) | 2014-04-13 | 2015-04-12 | 三機能性抗原結合分子 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170037128A1 (enExample) |
| EP (2) | EP2930188A1 (enExample) |
| JP (1) | JP6635940B2 (enExample) |
| KR (1) | KR102392598B1 (enExample) |
| CN (1) | CN106661108A (enExample) |
| AU (1) | AU2015249006B2 (enExample) |
| BR (1) | BR112016023362A2 (enExample) |
| CA (1) | CA2945053A1 (enExample) |
| DK (1) | DK3131928T4 (enExample) |
| MX (1) | MX382970B (enExample) |
| RU (1) | RU2753882C2 (enExample) |
| SI (1) | SI3131928T2 (enExample) |
| WO (1) | WO2015158636A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ726514A (en) | 2014-05-29 | 2019-01-25 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| MA44381A (fr) | 2015-06-15 | 2019-01-23 | Numab Innovation Ag | Format d'anticorps hétérodimères multispécifiques |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CA3053010A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| JP7542438B2 (ja) * | 2017-11-21 | 2024-08-30 | ノバルティス アーゲー | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
| WO2019101695A1 (en) * | 2017-11-21 | 2019-05-31 | Innate Pharma | Multispecific antigen binding proteins |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| JP2021512914A (ja) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法 |
| SG11202007945UA (en) | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JP7288913B2 (ja) * | 2018-03-14 | 2023-06-08 | アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク | 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN111527108A (zh) * | 2018-03-27 | 2020-08-11 | 西雅图免疫公司 | 制导和导航控制蛋白的制造和使用方法 |
| JOP20200303A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| AU2019327155A1 (en) | 2018-08-27 | 2021-03-18 | Affimed Gmbh | Cryopreserved NK cells preloaded with an antibody construct |
| CN114026122B (zh) | 2019-02-21 | 2024-12-31 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| US11591395B2 (en) | 2019-04-19 | 2023-02-28 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti-PSMA/CD3 antibody |
| WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| CR20210576A (es) | 2019-05-21 | 2021-12-15 | Novartis Ag | Moléculas de unión a cd19 y usos de las mismas |
| AU2020414409A1 (en) | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| BR112022021884A2 (pt) | 2020-05-06 | 2022-12-20 | Dragonfly Therapeutics Inc | Proteínas que se ligam a nkg2d, cd16 e clec12a |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| JP2023549116A (ja) * | 2020-11-06 | 2023-11-22 | アムジエン・インコーポレーテツド | 選択性が増大した多標的二重特異性抗原結合分子 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| PE20240761A1 (es) | 2021-01-28 | 2024-04-17 | Janssen Biotech Inc | Proteinas de union a psma y usos de estas |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| BR112023020832A2 (pt) | 2021-04-08 | 2023-12-19 | Marengo Therapeutics Inc | Moléculas multifuncionais ligadas a tcr e seus usos |
| IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Double structure antibodies |
| CN114044822B (zh) * | 2021-10-28 | 2023-06-27 | 杭州博茵生物技术有限公司 | 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用 |
| CN114316060B (zh) * | 2021-12-15 | 2023-06-13 | 北京市肿瘤防治研究所 | 抗人cd19与cd206双特异性抗体及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| EP0922111B1 (en) * | 1996-07-23 | 2004-12-01 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| ES2276735T3 (es) * | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| AU2002364531A1 (en) * | 2001-12-26 | 2003-07-24 | Ibc Pharmaceuticals | Methods of generating multispecific, multivalent agents from vh and vl domains |
| HRP20110187T1 (hr) * | 2003-10-16 | 2011-04-30 | Micromet Ag | Multispecifične deimunizirane tvari koje vežu cd3 |
| ES2595091T3 (es) * | 2005-12-21 | 2016-12-27 | Amgen Research (Munich) Gmbh | Composiciones farmacéuticas con resistencia a CEA soluble |
| NZ588554A (en) * | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| KR101431319B1 (ko) * | 2009-05-27 | 2014-08-20 | 에프. 호프만-라 로슈 아게 | 삼중특이성 또는 사중특이성 항체 |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| CA2815363C (en) * | 2010-10-22 | 2020-07-14 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
-
2014
- 2014-04-13 EP EP14164523.4A patent/EP2930188A1/en not_active Withdrawn
-
2015
- 2015-04-12 CA CA2945053A patent/CA2945053A1/en active Pending
- 2015-04-12 AU AU2015249006A patent/AU2015249006B2/en not_active Ceased
- 2015-04-12 CN CN201580019685.7A patent/CN106661108A/zh active Pending
- 2015-04-12 DK DK15719420.0T patent/DK3131928T4/da active
- 2015-04-12 SI SI201531107T patent/SI3131928T2/sl unknown
- 2015-04-12 KR KR1020167030836A patent/KR102392598B1/ko active Active
- 2015-04-12 WO PCT/EP2015/057919 patent/WO2015158636A1/en not_active Ceased
- 2015-04-12 MX MX2016013218A patent/MX382970B/es unknown
- 2015-04-12 RU RU2016138347A patent/RU2753882C2/ru active
- 2015-04-12 BR BR112016023362A patent/BR112016023362A2/pt active Search and Examination
- 2015-04-12 EP EP15719420.0A patent/EP3131928B2/en active Active
- 2015-04-12 JP JP2016562499A patent/JP6635940B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-11 US US15/290,255 patent/US20170037128A1/en not_active Abandoned
-
2021
- 2021-11-03 US US17/517,869 patent/US20220048994A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513476A5 (enExample) | ||
| RU2016138347A (ru) | Трифункциональная антигенсвязывающая молекула | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| PH12018501284A1 (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| JP2017504578A5 (enExample) | ||
| CN111601825A (zh) | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 | |
| MY207205A (en) | Cd3 antibody and pharmaceutical use thereof | |
| JP2014221064A5 (enExample) | ||
| RU2011143905A (ru) | ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab | |
| JP2017176174A5 (enExample) | ||
| EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| RU2014109557A (ru) | Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения | |
| MX2014002097A (es) | Anticuerpos bioespecificos especificos para antigenos que activan celulas t y un antigeno tumoral y metodos de uso. | |
| CL2011003148A1 (es) | Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso. | |
| JP2014533239A5 (enExample) | ||
| EA201790862A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| PE20211072A1 (es) | Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente | |
| WO2017132562A8 (en) | Antigen binding proteins that bind pd-l1 | |
| IN2014MN02293A (enExample) | ||
| AR098979A1 (es) | Los fragmentos fab de la inmunoglobulina en tándem y sus usos | |
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| RU2018102803A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2018522888A5 (enExample) |